Cargando…

A rare presentation of enfortumab vedotin–induced toxic epidermal necrolysis

Detalles Bibliográficos
Autores principales:	Francis, Andrea, Jimenez, Antonio, Sundaresan, Swaminathan, Kelly, Brent
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7727299/ https://www.ncbi.nlm.nih.gov/pubmed/33319007 http://dx.doi.org/10.1016/j.jdcr.2020.10.020

Ejemplares similares

Enfortumab Vedotin-Induced Toxic Epidermal Necrolysis: A Rare Fatal Adverse Reaction
por: Bansal, Aditi, et al.
Publicado: (2022)

Toxic epidermal necrolysis after the administration of enfortumab vedotin for urinary bladder urothelial carcinoma
por: Mimura, Yuji, et al.
Publicado: (2022)

Drug extravasation with Enfortumab vedotin
por: Grant, Christopher Ryan, et al.
Publicado: (2023)

Enfortumab Vedotin in urothelial cancer
por: Alt, Marie, et al.
Publicado: (2020)

Flexural Exanthema From Enfortumab Vedotin
por: Keerty, Dinesh, et al.
Publicado: (2020)

THU354 Enfortumab Vedotin Induced Refractory Hyperglycemia
por: Hussein, Marwah, et al.
Publicado: (2023)

Severe cutaneous drug toxicity following enfortumab vedotin treatment for metastatic urothelial carcinoma
por: Enescu, Christina D., et al.
Publicado: (2022)

Advancements in Therapy for Bladder Cancer: Enfortumab Vedotin
por: Hanna, Kirollos S.
Publicado: (2020)

Enfortumab Vedotin-induced Hyperglycemia and Ileal Conduit Reconstruction-induced Metabolic Acidosis
por: Sato, Takaaki, et al.
Publicado: (2023)

Two Cases of Exacerbation of Asthma during Treatment with Enfortumab Vedotin
por: Homma, Takamasa, et al.
Publicado: (2023)

Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin
por: Fahey, Catherine C., et al.
Publicado: (2023)

Cutaneous reactions with enfortumab vedotin: A case series and review of the literature
por: Dobry, Allison S., et al.
Publicado: (2021)

Toxic Epidermal Necrolysis induced by rarely implicated drugs
por: Rajagopalan, Sujit, et al.
Publicado: (2012)

Allopurinol-Induced Toxic Epidermal Necrolysis
por: Buenrostro-Rubio, Ignacio, et al.
Publicado: (2019)

Toxic epidermal necrolysis caused by etonogestrel implantation: A rare presentation
por: Amin, Minorvi, et al.
Publicado: (2022)

Bilateral Anterior Subcapsular Cataract Development Following Initiation of Enfortumab Vedotin
por: Thibodeau, Alexa, et al.
Publicado: (2021)

Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?
por: Maiorano, Brigida Anna, et al.
Publicado: (2023)

Toxic Epidermal Necrolysis
por: Khalifian, Saami, et al.
Publicado: (2014)

Carbamzepine-induced toxic epidermal necrolysis
por: Chowta, Nithyananda K., et al.
Publicado: (2011)

Toxic epidermal necrolysis induced by lansoprazole()
por: Fracaroli, Tainá Scalfoni, et al.
Publicado: (2013)

Fulvestrant-induced toxic epidermal necrolysis
por: Morales-Conde, Macarena, et al.
Publicado: (2019)

Pembrolizumab-Induced Toxic Epidermal Necrolysis
por: Borg, Luca, et al.
Publicado: (2022)

First Evidence of Activity of Enfortumab Vedotin on Brain Metastases in Urothelial Cancer Patients
por: Vulsteke, Christof, et al.
Publicado: (2023)

Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date
por: Moussa, Mohamad, et al.
Publicado: (2021)

Toxic epidermal necrolysis
por: Hoetzenecker, Wolfram, et al.
Publicado: (2016)

Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction
por: Viscuse, Paul V., et al.
Publicado: (2021)

Diabetic Ketoacidosis and Acute Kidney Injury Associated With Enfortumab Vedotin for Urothelial Carcinoma: A Case Report
por: Atemnkeng, Francis, et al.
Publicado: (2023)

Administration of Enfortumab Vedotin after Immune-Checkpoint Inhibitor and the Prognosis in Japanese Metastatic Urothelial Carcinoma: A Large Database Study on Enfortumab Vedotin in Metastatic Urothelial Carcinoma
por: Kawahara, Takashi, et al.
Publicado: (2023)

Cost-effectiveness of enfortumab vedotin in previously treated advanced urothelial carcinoma
por: Wu, Qiuji, et al.
Publicado: (2022)

Current and Emerging Treatments for Urothelial Carcinoma: A Focus on Enfortumab Vedotin
por: Shafique, Muhammad Ashir, et al.
Publicado: (2023)

Rapidly Developing Toxic Epidermal Necrolysis
por: Poulsen, Viktoria Oline Barrios, et al.
Publicado: (2013)

Toxic epidermal necrolysis in hemodialysis patient
por: Mateti, Uday Venkat, et al.
Publicado: (2015)

Pneumonia caused by toxic epidermal necrolysis
por: Doyle, Dominic, et al.
Publicado: (2022)

Lamotrigine-associated toxic epidermal necrolysis
por: Farooq, Omair, et al.
Publicado: (2023)

A Rare Case of Pertuzumab-Induced Toxic Epidermal Necrolysis
por: Mohamed Jiffry, Mohamed Zakee, et al.
Publicado: (2023)

Fatal case of cephalexin-induced toxic epidermal necrolysis
por: Hafermann, Matthew J, et al.
Publicado: (2014)

Pembrolizumab-induced toxic epidermal necrolysis: case report
por: Chow, Kar Ven Cavan, et al.
Publicado: (2022)

Ofloxacin-induced toxic epidermal necrolysis
por: Gupta, Gaurang
Publicado: (2014)

Levofloxacin-Induced Toxic Epidermal Necrolysis
por: Khan, Andeebia A, et al.
Publicado: (2023)

Phenytoin-Induced Toxic Epidermal Necrolysis
por: Tunuguntla, Mounika Nagarani, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gkleei25m2klj57n30pfcumvu7